Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues

Cancer

Volumn 88, Issue 2, 2000, Pages 407-415

  Chang, Sam S ^a   Reuter, Victor E ^a   Heston, W D W ^a   Hutchinson, Brian ^a   Grauer, Lana S ^b   Gaudin, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Hybritech Incorporated   (United States)

Author keywords

Androgen deprivation therapy; Monoclonal antibody; Prostate carcinoma; Prostate specific membrane antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATECTOMY;

AGED; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0034650721     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000115)88:2<407::AID-CNCR23>3.0.CO;2-0     Document Type: Article

References (30)

1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987;7: 927-36.
2. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990;50:6423-9.
3. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
4. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3: 81-5.
5. Wright GL, Haley C, Beckett ML, Schelhammer PF. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1995;1:18-28.
6. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34.
7. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, et al. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 1995;72:583-8.
8. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998;1443:113-27.
9. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-3.
10. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51.
11. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-53.
12. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998;286:1020-5.
13. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997;49:104-12.
14. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998;37:261-9.
15. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998;23:672-7.
16. Kahn D, Williams RD, Manyak MI, Haseman MK, Seldin DW, Libertino JA, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group [see discussion]. J Urol 1998;159:2041-7.
17. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83:2259-69.
18. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
19. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62:552-8.
20. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-9.
21. Wright GL Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34.
22. Cookson MS, Sogani PC, Russo P, et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a Phase II study [see comments]. Br J Urol 1997;9:432-8.
23. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer staging manual. Philadelphia: J.B. Lippincott, 1997.
24. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
25. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
26. Vailancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996;20:86-93.
27. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-61.
28. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-4.
29. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
30. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 1998;4:2669-76.